aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-10 16:18Core Viewpoint - A securities class action lawsuit has been filed against aTyr Pharma, Inc. for allegedly disseminating false and misleading statements regarding the efficacy of its drug Efzofitimod during a clinical trial [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased aTyr Pharma common stock between January 16, 2025, and September 12, 2025, with a lead plaintiff deadline set for December 8, 2025 [1][6]. - The complaint claims that aTyr Pharma concealed material adverse facts about Efzofitimod's ability to allow patients to taper steroid usage [3]. Group 2: Clinical Trial Results - aTyr Pharma conducted a Phase 3 study (EFZO-FIT) to evaluate Efzofitimod's safety and efficacy in patients with pulmonary sarcoidosis [3]. - On September 15, 2025, aTyr Pharma announced that the EFZO-FIT study failed to meet its primary endpoint regarding the reduction of mean daily oral corticosteroid dose at week 48 [4]. Group 3: Stock Price Impact - Following the announcement of the disappointing trial results, aTyr Pharma's stock price plummeted by 83.2%, dropping from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025 [5]. Group 4: Legal Representation - Investors affected by the stock price decline are encouraged to contact Shamis & Gentile, P.A. for information on seeking recovery claims [2][6].